Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 763,900 shares, an increase of 77.1% from the March 31st total of 431,400 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average trading volume of 200,900 shares, the days-to-cover ratio is currently 3.8 days.
Analyst Ratings Changes
PRAX has been the subject of several recent analyst reports. Wedbush boosted their price objective on shares of Praxis Precision Medicines from $16.00 to $29.00 and gave the stock a “neutral” rating in a research note on Friday, January 12th. Jefferies Financial Group boosted their target price on shares of Praxis Precision Medicines from $75.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $105.00 target price on shares of Praxis Precision Medicines in a research report on Friday.
Read Our Latest Analysis on Praxis Precision Medicines
Institutional Trading of Praxis Precision Medicines
Praxis Precision Medicines Trading Up 3.6 %
NASDAQ:PRAX opened at $54.80 on Friday. The company has a market cap of $725.44 million, a PE ratio of -2.32 and a beta of 2.89. Praxis Precision Medicines has a twelve month low of $12.45 and a twelve month high of $67.21. The company’s 50 day moving average is $51.97 and its two-hundred day moving average is $34.54.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($2.97) earnings per share for the quarter, topping the consensus estimate of ($3.05) by $0.08. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,037.88% and a negative return on equity of 151.02%. As a group, analysts expect that Praxis Precision Medicines will post -8.64 EPS for the current fiscal year.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Recommended Stories
- Five stocks we like better than Praxis Precision Medicines
- How to Calculate Options Profits
- 3 Stocks Leading the U.S. Agriculture Comeback
- Basic Materials Stocks Investing
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The “How” and “Why” of Investing in 5G Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.